title: Barrier coated drug layered particles for enhanced performance of amorphous solid dispersion dosage form.
abstract: Amorphous solid dispersions (ASDs) may entail tailor-made dosage form design to exploit their solubility advantage. Surface phenomena dominated the performance of amorphous celecoxib solid dispersion (ACSD) comprising of amorphous celecoxib (A-CLB), polyvinylpyrrolidone, and meglumine (7:2:1, w/w). ACSD cohesive interfacial interactions hindered its capsule dosage form dissolution (Puri V, Dhantuluri AK, Bansal AK 2011. J Pharm Sci 100:2460-2468). Furthermore, ACSD underwent significant devitrification under environmental stress. In the present study, enthalpy relaxation studies revealed its free surface to contribute to molecular mobility. Based on all these observations, barrier coated amorphous CLB solid dispersion layered particles (ADLP) were developed by Wurster process, using microcrystalline cellulose as substrate and polyvinyl alcohol (PVA), inulin, and polyvinyl acetate phthalate (PVAP) as coating excipients. Capsule formulations of barrier coated-ADLP could achieve rapid dispersibility and high drug release. Evaluation under varying temperature and RH conditions suggested the crystallization inhibitory efficiency in order of inulin < PVA ≈ PVAP; however, under only temperature treatment, crystallization inhibition increased with increase in T(g) of the coating material. Simulated studies using DSC evidenced drug-polymer mixing at the interface as a potential mechanism for surface stabilization. In conclusion, surface modification yielded a fast dispersing robust high drug load ASD based dosage form.
authors.affiliation: Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research,SAS Nagar 160-062, Punjab, India.
authors.forename: Vibha
authors.initials: V
authors.lastname: Puri
authors.forename: Ajay K
authors.initials: AK
authors.lastname: Dantuluri
authors.forename: Arvind K
authors.initials: AK
authors.lastname: Bansal
mesh_terms: D002214:Capsules / Q000737:chemistry*; D000068579:Celecoxib; D002482:Cellulose / Q000737:chemistry; D002626:Chemistry, Pharmaceutical / Q000379:methods*; D020099:Coated Materials, Biocompatible / Q000737:chemistry; D003460:Crystallization / Q000379:methods; D004339:Drug Compounding / Q000379:methods*; D004355:Drug Stability; D005079:Excipients / Q000737:chemistry*; D007444:Inulin / Q000737:chemistry; D008536:Meglumine / Q000737:chemistry; D004364:Pharmaceutical Preparations / Q000737:chemistry*; D011142:Polyvinyl Alcohol / Q000737:chemistry; D011145:Polyvinyls / Q000737:chemistry; D011205:Povidone / Q000737:chemistry; D011720:Pyrazoles / Q000737:chemistry; D012995:Solubility; D013449:Sulfonamides / Q000737:chemistry; D013696:Temperature
chemical_list: D002214:Capsules; D020099:Coated Materials, Biocompatible; D005079:Excipients; D004364:Pharmaceutical Preparations; D011145:Polyvinyls; D011720:Pyrazoles; D013449:Sulfonamides; C013215:polyvinyl acetate; D008536:Meglumine; D011142:Polyvinyl Alcohol; D002482:Cellulose; D007444:Inulin; D011205:Povidone; D000068579:Celecoxib; C109691:microcrystalline cellulose